Gene · 554
Papers2,697
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 2,697
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sex matters: The impact of oxytocin on healthy conditions and psychiatric disorders. | Compr Psychoneuroendocrinol | 2023 | 36590869 | PubTator, text mining | PubMed |
| Optical-Controlled Kinetic Switch: Fine-Tuning of the Residence Time of an Antagonist Binding to the Vasopressin V2 Receptor in In Vitro, Ex Vivo, and In Vivo Models of ADPKD. | J Med Chem | 2023 | 36563185 | PubTator, text mining | PubMed |
| Kidney concentrating capacity in children with autosomal recessive polycystic kidney disease is linked to glomerular filtration and hypertension. | Pediatr Nephrol | 2023 | 36538056 | PubTator, text mining | PubMed |
| Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. | J Intern Med | 2023 | 36511653 | PubTator, text mining | PubMed |
| Pro-haemostatic effect of DDAVP is partially derived through non-classical (CD14dim /CD16++ ) monocytes residing the spleen. | J Cell Mol Med | 2023 | 36479816 | PubTator, text mining | PubMed |
| Genetic basis of nephrogenic diabetes insipidus. | Mol Cell Endocrinol | 2023 | 36460218 | PubTator, text mining | PubMed |
| Effects of maternal hypertension on cord blood Arginine vasopressin receptor expression. | Pregnancy Hypertens | 2023 | 36435036 | PubTator, text mining | PubMed |
| Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies. | Clin Transl Sci | 2023 | 36382716 | PubTator, text mining | PubMed |
| Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease. | J Med Ultrason (2001) | 2023 | 36333536 | PubTator, text mining | PubMed |
| Polyuria in patients with lower urinary tract symptoms: Prevalence and etiology. | Neurourol Urodyn | 2023 | 36317410 | PubTator, text mining | PubMed |
| A transcriptome analysis of basal and stimulated VWF release from endothelial cells derived from patients with type 1 VWD. | Blood Adv | 2023 | 36121439 | PubTator, text mining | PubMed |
| Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis. | Int Urol Nephrol | 2023 | 36069961 | PubTator, text mining | PubMed |
| Mechanistic insights into the primary and secondary alterations of renal ion and water transport in the distal nephron. | J Intern Med | 2023 | 35909256 | PubTator, text mining | PubMed |
| Hierarchical attention network for multivariate time series long-term forecasting. | Appl Intell (Dordr) | 2023 | 35730045 | PubTator, text mining | PubMed |
| A Case Report of Tuberous Sclerosis and Autosomal Dominant Polycystic Kidney Disease in the Era of Tolvaptan. | Curr Rev Clin Exp Pharmacol | 2023 | 35585803 | PubTator, text mining | PubMed |
| A clinical approach to tubulopathies in children and young adults. | Pediatr Nephrol | 2023 | 35585366 | PubTator, text mining | PubMed |
| Nephrogenic Syndrome of Inappropriate Antidiuresis Mimicking Hyporeninemic Hypoaldosteronism: Case Report of Two Infants | J Clin Res Pediatr Endocrinol | 2023 | 34645113 | PubTator, text mining | PubMed |
| Vaptans or voluntary increased hydration to protect the kidney: how do they compare? | Nephrol Dial Transplant | 2023 | 34586414 | PubTator, text mining | PubMed |
| Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan. | Front Nephrol | 2022 | 37674994 | PubTator, text mining | PubMed |
| Genome assembly of the numbat (Myrmecobius fasciatus), the only termitivorous marsupial. | GigaByte | 2022 | 36824518 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/554/papers?page=20